Articles

Lilly losing dominance in diabetes treatment

Eli Lilly and Co., after more than a decade of setbacks, is counting on diabetes to help it survive a string of patent losses on other products that have begun to sap the drugmaker’s sales.

Read More

Spate of Indiana firms lines up for IPOs

The highest-profile Hoosier initial public offering was staged by Angie’s List Inc., the online provider of consumer reviews. The Indianapolis-based company raised $76 million by selling new shares, and existing stockholders raked in another $31 million by selling some of their holdings.

Read More

Finish Line got strong start to holiday season

For the three-week period ended Dec. 18, the Indianapolis-based athletic apparel retailer said sales in stores open at least a year increased 7 percent from the same time last year. For the entire quarter, company profit increased 35 percent, to $5.5 million.

Read More

Lilly enters drug-development deal with Immunogen

Cancer treatment developer Immunogen Inc. said Tuesday it will receive $20 million from Eli Lilly and Co. and could earn about $200 million in milestone payments under a collaboration agreement with the Indianapolis drugmaker.

Read More

Cracker Barrel rebuffs Biglari

Cracker Barrel shareholders appear to have rejected Sardar Biglari’s move to join the restaurant chain’s board, but stopped short of passing a “poison pill” plan that would deter outside investors from taking over the business.

Read More

Third-quarter profit dips at OneAmerica

OneAmerica earned $15.4 million in the three months ended Sept. 30, down 53 percent from the same quarter a year ago. Most of that difference came from a 17-percent jump in policy benefit payments.

Read More